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The airway microbiome in patients with severe asthma:
Associations with disease features and severity
Yvonne J. Huang, MD,a Snehal Nariya, BS,b Jeffrey M. Harris, MD, PhD,c Susan V. Lynch, PhD,d David F. Choy, BS,c
Joseph R. Arron, MD, PhD,c and Homer Boushey, MDb Ann Arbor, Mich, and San Francisco and South San Francisco, CalifBackground: Asthma is heterogeneous, and airway dysbiosis is
associated with clinical features in patients with mild-to-
moderate asthma. Whether similar relationships exist among
patients with severe asthma is unknown.
Objective: We sought to evaluate relationships between the
bronchial microbiome and features of severe asthma.
Methods: Bronchial brushings from 40 participants in the
Bronchoscopic Exploratory Research Study of Biomarkers in
Corticosteroid-refractory Asthma (BOBCAT) study were
evaluated by using 16S ribosomal RNA–based methods.
Relationships to clinical and inflammatory featureswere analyzed
among microbiome-profiled subjects. Secondarily, bacterial
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874severe asthma and previously studied healthy control subjects
(n5 7) and patients with mild-to-moderate asthma (n5 41).
Results: In patients with severe asthma, bronchial bacterial
composition was associated with several disease-related
features, including body mass index (P < .05, Bray-Curtis
distance-based permutational multivariate analysis of variance;
PERMANOVA), changes in Asthma Control Questionnaire
(ACQ) scores (P < .01), sputum total leukocyte values (P 5 .06),
and bronchial biopsy eosinophil values (per square millimeter,
P 5 .07). Bacterial communities associated with worsening ACQ
scores and sputum total leukocyte values (predominantly
Proteobacteria) differed markedly from those associated with
body mass index (Bacteroidetes/Firmicutes). In contrast,
improving/stable ACQ scores and bronchial epithelial gene
expression of FK506 binding protein (FKBP5), an indicator of
steroid responsiveness, correlated with Actinobacteria. Mostly
negative correlations were observed between biopsy eosinophil
values and Proteobacteria. No taxa were associated with a TH2-
related epithelial gene expression signature, but expression of
TH17-related genes was associated with Proteobacteria. Patients
with severe asthma compared with healthy control subjects or
patients with mild-to-moderate asthma were significantly
enriched in Actinobacteria, although the largest differences
observed involved a Klebsiella genus member (7.8-fold increase
in patients with severe asthma, adjusted P < .001).
Conclusions: Specific microbiota are associated with and may
modulate inflammatory processes in patients with severe asthma
and related phenotypes. Airway dysbiosis in patients with
severe asthma appears to differ from that observed in those
with milder asthma in the setting of inhaled corticosteroid use.
(J Allergy Clin Immunol 2015;136:874-84.)
Key words: Microbiota, lung, inflammation, 16S ribosomal RNA,
body mass index, asthma control, steroids, TH2
Discuss this article on the JACI Journal Club blog: www.jaci-
online.blogspot.com.
The spectrum of heterogeneity in asthmatic patients includes
those with severe disease whose symptoms remain inadequately
controlled despite treatment with current therapies.1,2 Impor-
tantly, heterogeneity within patients with severe asthma also has
been described.3,4 Different pathologic mechanisms have been
proposed to underlie various asthma phenotypes,5 including those
meeting the criteria for severe disease.6
Recent studies have expanded considerations of the role of
microbial infection or colonization in asthmatic patients.7-10 Re-
ported observations include differences in lower airway bacterial
composition between asthmatic and healthy subejcts7-9,11 charac-
terized by a greater prevalence in asthmatic patients of
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markers in Corticosteroid-refractory AsthmaFKBP5: FK506 binding proteinPB: Protected brushPERMANOVA: Permutational multivariate analysis of variancePICRUSt: Phylogenetic Investigation of Communities by
Reconstruction of Unobserved StatesqPCR: Quantitative PCR16S rRNA: 16S Ribosomal RNAProteobacteria, a large phylum that includes many potential
respiratory pathogens. This prevalence of Proteobacteria also has
been observed among patients with mild asthma not taking
regular inhaled corticosteroid therapies,7 suggesting that the pres-
ence of airway dysbiosis is associated with asthma itself and not
simply a reflection of concurrent corticosteroid treatment.
In patientswithmild-to-moderate asthma, relationships between
the airway microbiome and clinical features have been observed.8
Whether similar relationships exist in patients with severe asthma
are unknown. To address this knowledge gap, we examined the
bacterial microbiome in protected bronchial brushings collected
from patients with severe asthma in the Bronchoscopic Explor-
atory Research Study of Biomarkers in Corticosteroid-refractory
Asthma (BOBCAT) study.12 Bacterial composition was analyzed
by using 16S ribosomal RNA (16S rRNA)–based methods, fol-
lowed by in silico predictive metagenomic analysis of bacterial
groups of interest. We identified significant relationships between
airway microbiota members and features of severe asthma. Addi-
tional analyses demonstrated differences in bronchial microbiota
composition between this severe asthma cohort and healthy control
subjects and patients with mild-to-moderate asthma, whose bron-
chialmicrobiomeswere examined in an earlier study.8 Our primary
findings invite speculation that features of the bronchial micro-
biome can contribute to endotypes of severe asthma.METHODS
Patients with severe asthma and sample processing
for microbiome analysis
As previously described,12 the BOBCAT study was a multicenter, 3-visit
study that enrolled 67 patients with severe asthma, which was defined as an
FEV1 of 40% to 80% of predicted value, an Asthma Control Questionnaire
(ACQ) score of greater than 1.50, and a daily inhaled corticosteroid dose
equivalent to 1000 mg of beclomethasone or greater. Subjects underwent
sputum induction (visit 2), bronchoscopy (visit 3), and blood sampling. Med-
ications were kept constant during the study; no corticosteroids or antibiotics
were started or changed from 30 days before visit 1 through visit 3.
To ensure total DNA was extracted from the same number of protected
brushes (PBs) for all evaluated subjects and on the basis of our prior
experience8 that brush extractions yield variable amounts of DNA, we
required at least 2 brushes to evaluate for microbiome analysis. Forty subjects
fulfilled this criterion, and 2 PBs (stored in RNAlater at 2808C) were ex-
tracted. Subjects’ characteristics were analyzed for differences between those
whose samples were (n5 40) or were not (n5 27) evaluated for microbiome
analysis by using nonparametric or parametric tests. Amplified 16S rRNA
gene products (using universal primers 27F and 1492R13) were processed
for profiling by using the 16S rRNA-based PhyloChip platform (Second
Genome, South San Francisco, Calif), as previously described.8,14Data analysis
Raw array data were processed, as previously described,15-17 including
scaling to spiked-in quantitative standards and normalization to themean inten-
sity of all samples. Bacterial taxa were identified based on 97% or greater iden-
tity in 16S rRNA gene sequences (Greengenes 2011 iteration18) by using
published methods.14,15,19 Details are available in the Methods section in this
article’s Online Repository at www.jacionline.org. Log2-transformed fluores-
cence intensities, which are correlative with the relative abundance of taxa,20
were used for all analyses in R software.Array datawere normalized separately
for exploratory analyses ofmicrobiota differences between patients with severe
asthma and previously studied8 healthy subjects and patients with mild-to-
moderate asthma fromwhom PB-sampled bacterial composition had been pro-
filed by the same platform (see data sets in Table E1 in this article’s Online Re-
pository at www.jacionline.org). The healthy control data set included 2
subjects not in the earlier study8 but who had been evaluated at the University
of California San Francisco by using the same criteria to exclude asthma.
a-Diversity for each samplewas calculated,21,22 including Shannon and in-
verse Simpson indices (number and relative distribution of taxa) and Faith
phylogenetic diversity, which additionally weights phylogenetic relation-
ships.23 Bray-Curtis and UniFrac distance measures24,25 were calculated to
evaluate between-sample compositional differences by means of ordination
analyses and in PERMANOVA tests with clinical and inflammatory vari-
ables.26 Correlation analyses or the Significance of Analysis of Microarrays
method, based on a univariate penalized regression approach,27 were used
to identify specific taxa-to-variable relationships. Adjustments for multiple
comparisons were applied (Benjamini-Hochberg [BH] correction or q
values28). For predictive metagenomic analyses, Phylogenetic Investigation
of Communities by Reconstruction of Unobserved States (PICRUSt)29 was
used to predict gene functions and KEGG pathways.
Airway epithelial gene expression analysis
RNA extracted from a separate epithelial brush was amplified for Agilent
(Santa Clara, Calif) 2-color Whole Human Genome 4x44k gene expression
microarray analysis. Universal Human Reference RNA (Stratagene, La Jolla,
Calif)was used for the reference channel. TH2 andTH17 scoreswere calculated
by means of case-wise averaging of zero-centered gene expression data after
annotation-based independent filtering30; that is, if multiple probes correspond
to an Entrez gene, the probe with the highest interquartile range was selected.
SERPINB2,CLCA1, andPOSTNwere used as IL-13–responsiveTH2 signature
genes, as described previously.31 CXCL1, CXCL2, CXCL3, IL8, and CSF3
were used as IL-17–responsive TH17 signature genes based on previous evi-
dence that expression of thesegenes is involved in IL-17–driven pathways.32-34
The data have been deposited in the National Center for Biotechnology Infor-
mation’s NCBI GEO database (accession no. GSE65584).
Quantitative PCR studies
Total 16S rRNA gene copies, as well as copy number determinations to
validate specific species of interest, were assessed by using quantitative PCR
(qPCR). Further details are provided in the Methods section in this article’s
Online Repository.
RESULTS
Characteristics of patients with severe asthma
PBs from 40 of 67 subjects in the BOBCAT study underwent
evaluation for bacterial microbiome analysis. Bacterial evalua-
tion was not pursued in the other 27 subjects because they lacked
the requisite number of 2 PBs for technical consistency in source
DNA extractions. Of the evaluated subjects, 30 demonstrated
sufficient amplified 16S rRNA product (prespecified threshold of
>_100 ng) for array-based profiling.
Characteristics of these subjects are summarized in Table I.
Mean FEV1 percent predicted (average of visit 1 and visit 2)
was 59%, with a mean ACQ score of 2.4, which is indicative of
poor control. qPCR experiments confirmed that this group had
TABLE I. Characteristics of the 30 patients with severe asthma
for whom bronchial microbiome analysis was performed
Age (y) 46 (20 to 63)
White race (%) 24 (80)
Female sex, no. (%) 11 (37)
BMI (kg/m2) 28.7 6 6.9 (19.3 to 52.1)
FEV1/FVC ratio 0.73 (0.55 to 1.0)
FEV1 (% predicted), visit 1 59.9 (34.3 to 77.7)
FEV1 (% predicted), visit 2 58.3 (33.6 to 82.8)
Bronchodilator reversibility (%) 13.7 (28.6 to 38.9)
ACQ score, visit 1 2.4 6 0.6
ACQ score, visit 2 2.4 6 0.8
Prednisolone use, no. (%) 6 (20)
FENO (ppb) 42.8 6 37.9 (9.7-141.5)
Sputum eosinophils (%) 5.5 6 5.9 (0.0 to 18.8)
Sputum neutrophils (%) 52.4 6 28.3 (0 to 88.3)
Blood absolute eosinophils (3 103/mL) 0.29 6 0.2
Serum IgE (IU/mL) 180.8 6 202.9 (9 to 835.2)
Serum periostin (ng/mL) 24.2 6 7.3
Values are means 6 SDs (percentages or ranges).
FENO, Fraction of exhaled nitric oxide representing the mean from visits 1 and 2; FVC,
forced vital capacity.
TABLE II. Clinical and inflammatory features of patients with
severe asthma demonstrating associations with differences in
bacterial community composition based on Bray-Curtis
distance measures
Variable
Distance-based PERMANOVA
result (P value)
BMI .05
ACQ score, visit 2 .05
ACQ score change (visit 22 visit 1) .01
Sputum total leukocyte value .06
Biopsy eosinophil cells (mm22) .07
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FIG 1. Nonmetric multidimensional scaling analysis (NMDS) based on
Bray-Curtis distances showing differences in bronchial bacterial composi-
tion among 30 patients with severe asthma. Each dot represents the overall
bacterial community in each subject. Vectors indicate linear regression–
based fits for variables found by using independent distance-based PER-
MANOVA testing to be associated with distinct bacterial compositions. Vec-
tor directions indicate that the specific communities associated with
differences in ACQ scores (ACQdiff) and sputum total leukocyte values
(SputLeuk) are similar to each other and differ from specific communities
associated with BMI and biopsy eosinophil values (BxEos).
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the other 10 evaluated subjects who had insufficient 16S rRNA
amplicons (ie, low bacterial burden) for array-based profiling
(P < .05, Wilcoxon rank sum test).
We examined whether characteristics differed among the
evaluated subjects between those in whom bacterial composi-
tional profiles were or were not successfully obtained. The
subjects in whom microbiome analysis could be performed had
significantly lower sputum eosinophil percentages (5.5%6 5.9%
vs 17.3% 6 21.1%, P < .05) and a trend toward lower bronchial
biopsy eosinophil numbers (31.8 6 33.7 vs 45.2 6 19.3 eosino-
phils/mm2, P 5 .09). We also analyzed whether characteristics
differed between BOBCAT study participants whose samples
were (n 5 40) or were not (n 5 27) evaluated for microbiome
profiling. The evaluated group had lower mean body mass index
(BMI; 29 vs 34 kg/m2, P <.01) but higher numbers of biopsied IL-
17A– and IL-17F–positive cells (P < .001 and P < .05, respec-
tively). In both sets of analyses, there were no significant differ-
ences between the compared subgroups in other clinical and
inflammatory parameters, including 3 examined gene expression
patterns (FK506 binding protein [FKBP5], TH2, and TH17).Severe asthma features are associated with
differences in airway bacterial composition
Distance-based PERMANOVA26 analyses (Bray-Curtis or
weighted UniFrac distances) were performed to identify factors
that might explain variation in microbial community composition
among samples (Table II). Identified factors included BMI
(P < .05), ACQ scores at visit 2 (P < .05), and changes in ACQ
scores during the study (visit 2 minus visit 1, P < .01). Associa-
tions that trended toward significance included sputum total
leukocyte percentages (P5 .06) and bronchial biopsy eosinophil
numbers (per square millimeter, P 5 .07). These observations
indicate that specific bacterial compositions are associated with
particular disease features in this cohort. No associations with
other assessed variables, including inflammatory measures from
blood or bronchoalveolar lavage fluid, were found (results for
all evaluated variables are available in Table E2 in this article’sOnline Repository at www.jacionline.org). To visualize these re-
lationships, ordination analysis was used (nonmetric multidimen-
sional scaling, Fig 1). Regression-based linear fits to this
ordination indicated that change in ACQ score and sputum total
leukocyte values were associated with microbiome compositions
distinct from those associated with BMI and biopsy eosinophil
numbers.Distinct microbiota members are associated with
different features of severe asthma
Taxon-level correlation analyses were performed between the
relative abundance of each detected taxon and each variable
across all subjects to identify specific bacterial taxa associated
with these variables of interest. Results confirmed the ordination
analyses in that taxa significantly associated with BMI were
distinct from those associated with the other features.
FIG 2. A, Relative abundance plotted against BMI for the 98 taxa found to be significantly correlated with
BMI among the patients with severe asthma studied (R 5 0.5-0.8, BH-adjusted P < .05). The distribution
of bacterial phyla representing these taxa are shown, which are mainly Bacteroidetes and Firmicutes. B, Dif-
ferences in the relative abundance of all detected taxa between obese (BMI > 30 kg/m2, n 5 10) and nonob-
ese (n 5 19) patients with severe asthma. Taxa significantly enriched among obese subjects (2-fold,
adjusted P < .10) include members of the Bacteroidetes and Firmicutes phyla, such as Prevotella species.
Dashed lines indicate a 2-fold difference (log2 5 1.0) and false discovery rate significance level of 10%,
respectively. Asterisks indicate taxa most significantly greater in abundance among obese subjects
(adjusted P < .05), which are also represented by larger circles in the plot.
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tively, of the 98 taxa significantly correlated with BMI (Pearson
R5 0.5-0.8; BH-adjusted P <.05; Fig 2, A). This contrasted with
the predominant representation of Proteobacteria among taxa un-
correlated with BMI (P <.01, x2 test). Further analysis for specific
compositional differences between obese (BMI >_ 30 kg/m2) and
nonobese subjects identified several taxa more abundant among
obese subjects (R package limma moderated t test, BH-adjusted
P <.05; Fig 2, B). These included members of the Prevotellaceae,
Mycoplasmataceae, Lachnospiraceae (Clostridium species), and
Spirochaetaceae (Treponema species; see Table E3 in this article’sOnline Repository at www.jacionline.org). Given this, we
explored whether obese and nonobese subjects in this
microbiome-profiled group differed in other characteristics. The
only significant finding was that obese subjects had fewer biopsy
eosinophils than nonobese subjects (mean biopsy eosinophil
numbers, 11.9/mm2 in subjects with high BMI vs 45.3/mm2 in
subjects with low BMI; P < .01).
In contrast to BMI, Proteobacteria represented the majority of
taxa (>90%) whose relative abundance correlated with worsening
ACQ scores (visit 2 minus visit 1 scores; R 5 0.5-0.7, BH-
adjusted P < .05; Fig 3, A). These included families representing
FIG 3. A, Relative abundance plotted against changes in ACQ scores for the bacterial taxa (n5 448) found to
be positively correlated with this parameter (R 5 0.5-0.7, BH-adjusted P < .05). Increasing values of the
change in ACQ score are associated with greater relative abundance predominantly of Proteobacteria mem-
bers. B, Relative abundance plotted against change in ACQ score for the bacterial taxa (n5 362) found to be
negatively correlatedwith changes in ACQ scores (R520.5 to20.8, BH-adjusted P < .05). Decreasing values
of the change in ACQ score are associated with greater relative abundance of predominantly members of
the Actinobacteria, followed by Firmicutes, phyla. C, Total 16S rRNA copy numbers, a proxy for bacterial
burden, are inversely correlated with absolute values of the change in ACQ score (Spearman r 5 20.54,
P < .01).
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HUANG ET AL 879known respiratory pathogens, such as Pasteurellaceae, Enterobac-
teriaceae, Neisseriaceae, Burkholderiaceae, and Pseudomonada-
ceae. Similar results were observed among communities
significantly correlated with higher visit 2 ACQ scores (see Fig
E1 in this article’s Online Repository at www.jacionline.org). In
contrast, taxa correlated with improving or stable ACQ scores
were primarily Actinobacteria (80%; Fig 3, B), such as Strepto-
mycetaceae, Nocardiaceae, and Mycobacteriaceae. Analyses
with absolute values of the change in ACQ score, presumably a
reflection of instability in asthma control, also showed Proteobac-
teria to most represent positively correlated communities (40/91
taxa; R 5 0.4-0.6, q < 0.15). Total 16S rRNA copy numbers
demonstrated an inverse relationship to absolute values of the
change in ACQ score (Spearman r 5 20.54, P < .01; Fig 3, C),
with a similar trend observed with inverse Simpson diversity
(R 5 20.37, P 5 .09), suggesting that greater bacterial burden
in general is associated with less variation in asthma control.
Proteobacteria also constituted the majority of taxa (71% [73/
103] of taxa) significantly correlated with sputum total leukocyte
numbers (mean 6 SD, 812 6 678 cells/mL). Families with
members demonstrating strong correlations with this parameter
(R5 0.6-0.8, BH-adjusted P < .05) included the Enterobacteria-
ceae and Moraxellaceae. Total 16S rRNA copy numbers signifi-
cantly correlated with sputum total leukocyte numbers (R5 0.4,
P < .05), which indicates that bacterial burden is associated with
increased numbers of inflammatory cells.
In contrast, significant but predominantly negative associations
were seen between biopsy eosinophil numbers and the relative
abundance of specific bacteria (71 taxa, R 5 20.5 to 20.74,
q < 0.10). These negatively correlated communities were mostly
Proteobacteria (64% [45/71] of taxa), followed by Firmicutes, and
included members of the Moraxellaceae and Helicobacteraceae
(see Table E4 in this article’s Online Repository at www.
jacionline.org). Only 2 taxa demonstrated a significant positive
correlation with biopsy eosinophil numbers, both Actinobacteria
(Streptomyces and Propionicimonas species). Total 16S rRNA
copy numbers were also inversely correlated with biopsy eosino-
phil numbers (R 5 20.50, P < .01; Fig 4, A), suggesting that
higher bacterial burden is associated with less eosinophil infiltra-
tion in bronchial tissue. We did not observe relationships between
bacterial composition and other indicators of eosinophilic inflam-
mation (eg, sputum or blood eosinophil, fraction of exhaled nitric
oxide, and periostin values).Bacterial microbiota are associated with specific
airway epithelial gene expression signatures
For 33 of the 40 subjects evaluated for bacterial profiling,
matched airway epithelial gene expression microarray analysis
was performed (23/30 microbiome-profiled and 10/10 non–
microbiome-profiled subjects). Brushes analyzed for epithelial
gene expression were collected concurrently with those evaluated
for microbiome profiling, presenting a unique opportunity to
explore contemporaneous relationships between the microbiome
and local host epithelial gene expression. We specifically
explored relationships to 3 gene expression patterns identified
by using microarray analysis: a marker of steroid response
(FKBP5), TH2-associated inflammation (POSTN, CLCA1, and
SERPINB2),5 and TH17-associated inflammation involving genes
previously shown to be involved in IL-17–driven pathways
(CXCL1, CXCL2, CXCL3, CXCL8, and CSF3).32-34Positive associations were observed between FKBP5 expres-
sion and the relative abundance of 83 taxa (q < 0.10, Significance
of Analysis of Microarrays), largely Actinobacteria (58%) and
Proteobacteria (27%; Fig 4, B). Bacterial diversity measures
were also significantly correlated with FKBP5 expression
(R 5 0.5, P < .01; Fig 4, C), indicating that transcriptional evi-
dence of steroid response is associated with increased community
diversity.
No significant associations were observed between microbiota
members and the TH2-related gene signature (at false discovery
rate thresholds of up to 0.20). At a higher cutoff (q < 0.25), 16
taxa demonstrated negative associations with this gene signature.
These included members of the Moraxellaceae and Helicobacter-
aceae, which were also represented among taxa negatively corre-
lated with biopsy eosinophil numbers (see Table E4).
Positive correlations with the TH17-associated gene expres-
sion pattern were observed for a number of taxa. These commu-
nities were mainly Proteobacteria (72% [80/110] of taxa;
R 5 0.5-0.7, P < .04, q < 0.20), such as Pasteurellaceae, Entero-
bacteriaceae, and Bacillaceae (see Table E5 in this article’s On-
line Repository at www.jacionline.org). Although Proteobacteria
also represented a proportion of taxa correlated with FKBP5
expression, the particular families largely did not overlap with
those Proteobacteria families positively associated with the
TH17 expression pattern. Only 11 Proteobacteria families were
represented in both gene signatures among correlated taxa,
which is in contrast to the many more Proteobacteria families
associated with either signature (41 families represented only
among FKBP5-correlated taxa and 57 families represented
only among TH17-correlated taxa). The compositional dissimi-
larity of taxa correlated with these 2 expression patterns was
also evident by using nonmetric multidimensional scaling anal-
ysis (Fig 5). This suggests particular airway microbiota might
promote TH17 inflammation, resulting in neutrophil recruitment
and contributing to neutrophilic airway inflammation indepen-
dent of steroid-induced effects.Predicted community functions of specific taxa
related to severe asthma features
Shotgun metagenomic sequencing approaches can provide
insight into the functional capacities of microbiota but to do so at
high resolution is challenging. To explore the predicted functional
capacity of identified taxa of interest in this study, we applied an
alternative, informatics-based approach called PICRUSt,29 which
uses 16S rRNA sequence information to infer bacterial metage-
nomes and was shown to recapitulate results of actual metage-
nomic sequencing from the Human Microbiome Project.
Representative 16S rRNA sequences for taxa demonstrating
significant associations (positive and negative) with variables of
interest in this study were inputted into PICRUSt. The outputs are
predicted functions defined as KEGG gene orthologs and repre-
sented as KEGG pathways where these functions are known to be
involved. For example, predicted functions present among taxa
correlated with BMI (see Fig E2 in this article’s Online Repository
at www.jacionline.org) included pathways in carbohydrate diges-
tion and absorption, insulin signaling, and microbially related
signaling and inflammation (eg, NOD-like receptor signaling, bac-
terial toxins and epithelial cell signaling in Helicobacter species
infection). This suggests that particular airway-associated micro-
biota might incite inflammatory responses among overweight/
FIG 4. A, Total 16S rRNA copy numbers, a proxy for bacterial burden, are inversely correlated with biopsy
eosinophil cell numbers (R520.50, P < .01). Data shown represent 29 of 40 subjects, including the subjects
in whom array-based bacterial community profiling could not be performed because of low bacterial con-
tent. B, The relative abundance of bacterial taxa (n 5 83, q < .10) associated with FKBP5 expression plotted
against the relative expression values for this gene. Phylum-level classification of these correlated commu-
nities is shown. C, Strongly significant correlations are seen between FKBP5 expression and 2 differentmea-
sures of bacterial community diversity: Faith phylogenetic diversity and the inverse Simpson diversity
index. The former weights phylogenetic relationships among communities in the diversity determination,
whereas the latter reflects primarily community richness and evenness.
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FIG 5. Compositionally distinct bacterial taxa are positively associated with
FKBP5 expression (green Fs; n 5 83; 58% Actinobacteria) and the TH17-
related gene expression pattern (red Ts; n 5 110; 72% Proteobacteria).
The nonmetric multidimensional scaling (NMDS) ordination is based on a
Bray-Curtis distance matrix for all associated taxa in both expression pat-
terns. Ellipses represent the 95% CIs for the SDs of the distances for each
group.
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HUANG ET AL 881obese asthmatic patients in this cohort. Analysis results for pre-
dicted functions among taxa associated with asthma control
(ACQ score change) and with FKBP5 and TH17-related gene
expression pattern are shown in Figs E3 and E4 in this article’s On-
line Repository at www.jacionline.org.Bronchial microbiota differences between patients
with severe asthma, healthy control subjects, and
patients with mild-to-moderate asthma
We explored whether bronchial bacterial composition differs
in patients with severe asthma from that profiled from previously
studied healthy control subjects (n5 7) or patients with mild-to-
moderate asthma who were receiving low-dose inhaled steroids
(n5 41, 88mg of fluticasone propionate twice daily).8 Compared
with healthy control subjects (Fig 6, A, and see Table E6 in this
article’s Online Repository at www.jacionline.org), patients
with severe asthmawere enriched in several taxa, with the largest
fold difference seen in a Klebsiella species (moderated t statistic
linear models, R package limma, BH-adjusted P < .001).
Compared with patients with mild-to-moderate asthma (Fig 6,
B, and see Table E6), patients with severe asthma also were
significantly enriched in 53 taxa, with the majority being Actino-
bacteria (47/53) and the remaining 5 taxa classifying to Gam-
maproteobacteria (all Enterobacteriaceae). The latter included
a Klebsiella species that, as in the comparison with healthy con-
trol subjects, exhibited the highest fold difference in relative
abundance (7.9-fold increase in patients with severe asthma,
BH-adjusted P <.0001). Conversely, 42 taxa weremore abundant
in patients with mild-to-moderate asthma relative to the group
with severe asthma. These taxa represented members from mul-
tiple phyla, with several different families of Proteobacteria (19
taxa) being most represented. This contrasted from the reversecomparison wherein Enterobacteriaceae was the sole family of
Proteobacteria with enriched members in patients with severe
asthma.qPCR studies
qPCR with primers specific for Haemophilus influenzae,14 a
Pasteurellaceae member associated with worsening ACQ scores
and expression of TH17-related genes, confirmed a significant
correlation between b-actin–normalized log copies of H influen-
zae and fluorescence intensities for the H influenzae–represented
taxon (r5 0.67, P < .02). qPCR also confirmed a strong correla-
tion between Prevotella species abundance in samples and
increased BMI (r5 0.61, P < .05; see Fig E5 in this article’s On-
line Repository at www.jacionline.org) by using primers targeting
specific Prevotella species represented in the BMI-associated
taxa. Prevotella species copy numbers were also significantly
higher in obese versus nonobese subjects (P < .05).DISCUSSION
In this cohort of adults with severe asthma, we observed
significant relationships between the bronchial airway micro-
biome and clinical and inflammatory features. The findings
suggest that specific members of the airway microbiota are
associated with putative phenotypes of severe asthma, such as
those characterized by obesity-associated disease, corticosteroid-
responsive disease, or TH17-associated airway inflammation.
Interestingly, microbiome-associated clinical features in this study
(eg, obesity and poor symptom control) are characteristics previ-
ously described among patients with some severe asthma pheno-
types.4 A key strength of this study was the capacity to explore
microbiome relationships to severe asthma–related clinical and in-
flammatory measures in different compartments, including blood
and the lower airways. This enabled a comprehensive examination
of possible microbiota relationships to underlying pathophysio-
logic processes reflected in these measures. Also, we explored
and identified differences in bronchial bacterial composition be-
tween patients with severe asthma and healthy control subjects
and patients with mild-to-moderate asthma whose bronchial mi-
crobiota had previously been characterized.8 Overall, our findings
invite speculation that patterns of airway dysbiosis can contribute
to putative endotypes of severe asthma or even asthma in general.
Among patients with severe asthma, BMI was strongly
correlated with particular microbiota members, specifically
Bacteroidetes and Firmicutes. This pattern is in striking contrast
to the increased prevalence of Proteobacteria observed in patients
with milder asthma7-9 and other feature correlations observed in
this study. Obese patients with severe asthma also had fewer bi-
opsy eosinophil numbers than subjects with lowBMI. This invites
speculation about whether members of the Bacteroidetes and Fir-
micutes might influence the degree of eosinophilic inflammation
seen in airway biopsy specimens or, alternatively, stimulate non–
eosinophil-associated immune responses. These 2 phyla also
represent gastrointestinal microbiota, suggesting the possibility
of aspiration. Whether the observed BMI-associated taxa
contribute to asthmatic airway inflammation cannot be answered
from this study, but other lines of evidence suggest they could.
Species of Prevotella species represented among these taxa are
potential pathogens previously associated with periodontitis and
arthritis,35,36 whereas Lachnospiraceae belong to a Clostridia
FIG 6. A, Heat map of the 10 taxa found to be significantly enriched among patients with severe asthma
(n 5 30) compared with healthy control subjects (n 5 7; BH-adjusted P < .15; R package limma). B, Heat
map of the 95 total taxa found to significantly differ in relative abundance between patients with severe
asthma (n 5 30) and those with mild-to-moderate asthma (n 5 41; >_2-fold difference; BH-adjusted
P < .01; R package limma). Relative to the other group, patients with severe asthma were enriched in 53
taxa, whereas patients with mild-to-moderate asthma were conversely enriched in 42 taxa.
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positive regulatory T cells.37,38 Thus there is precedent for the ca-
pacity of these organisms to potentially promote or regulate
inflammation in the respiratory tract. This paralleled results
from our predictive metagenomic analysis, suggesting the
inflammation-eliciting potential of these communities.
Worsening ACQ scores among patients with severe asthma
were associated with greater relative abundance of Proteobac-
teria (eg, Enterobacteriaceae, Neisseriaceae, and Pasteurella-
ceae, families representing potential respiratory pathogens),
whereas improving/stable ACQ scores were associated with
Actinobacteria. Actinobacteria are metabolically diverse and
prolific producers of secondarymetabolites, includingmanywith
antimicrobial and anti-inflammatory properties.39 Interestingly,
Actinobacteria also were the main group of organisms associated
with molecular evidence of response to steroids (FKBP5 expres-
sion). This suggests the possibility of certain airway microbiota
being indicative of asthma responsive to steroids, adherence to
prescribed therapy, or even their involvement in mechanisms of
steroid response.
Study limitations include the site and timing of PB collection
and the exclusion of other parent study subjects. PBs evaluated for
microbiome analysis sampled at least 2 mucosal sites, with
concurrently collected brushes used for gene expression studies, astrength of this study. Although bronchoscopy followed earlier
visit measurements of variables considered in our analyses (eg,
ACQ score), there were no respiratory illnesses or medication
changes to have influenced the bacteria identified. We cannot
completely rule out possible biases related to the exclusion, for
technical reasons, of other parent study subjects. However, a
systematic analysis found only significant differences between
evaluated and nonevaluated BOBCAT study subjects in BMI and
biopsied numbers of IL-171 cells. Finally, the primary aim of our
study was to examine bronchial microbiome relationships to fea-
tures of patients with severe asthma. No control group was
enrolled and identically studied in the BOBCAT study. Therefore
we performed a focused comparison of bronchial bacterial
composition in patients with severe asthma with that profiled pre-
viously by using the same methods from PBs of healthy control
subjects and patients with mild-to-moderate asthma studied
earlier.8
Despite study differences and other potential biases that cannot
be completely controlled, our findings suggest the following.
First, airway dysbiosis is a feature of severe asthma and differs
from that seen in patients with milder asthma receiving lower
doses of inhaled corticosteroids. Second, different microbiota,
even within the same bacterial phylum (eg, Proteobacteria),
family, or even genus are implicated in different phenotypic
FIG 6. Continued
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TH17-related or non–type 2 airway inflammation) to potential
modulation of treatment responses (eg, corticosteroids).
A surprising observation was the overall absence of positive
relationships between bacterial composition and indicators of
type 2–driven inflammation, from epithelial expression of type 2–
responsive genes to various markers of eosinophil-related inflam-
mation. Indeed, only biopsy eosinophil values demonstrated
significant but predominantly negative correlations with bacterial
microbiota members. The use of high-dose inhaled corticoste-
roids could suppress these measures, although the mean sputum
eosinophil percentage was increased among subjects in whom
microbiome profiling could be performed and these percentages
correlated with relative expression of the type 2–responsive
epithelial gene signature (Spearman r 5 0.53, P < .05). Other
markers (eg, fraction of exhaled nitric oxide, periostin, and blood
or sputum eosinophil values) also did not demonstrate relation-
ships to bacterial composition. Antibacterial effects of eosino-
phils are a consideration for these findings. However, because
DNA-based detection methods were used, we expect that any
DNA present from killed bacteria should still be detectable. Other
possibilities include that heterogeneity within the cohort maskedbacterial associations with type 2–related inflammation or that
other microbial kingdoms, such as fungi, which were previously
observed to be reciprocally related to bacterial abundance,40 play
a larger role in driving these responses.
Finally, we identified a group of mainly Proteobacteria sig-
nificantly associated with epithelial expression of TH17 inflamma-
tion–related genes.41 TH17 cells, through IL-17A and IL-17F,
promote neutrophil recruitment and have been invoked as a noneo-
sinophilic/non–type 2 pathway in asthmatic patients.42 Asthmatic
patients without evident type 2–driven inflammation are less
responsive to inhaled corticosteroids.5 In mice TH17 cell–medi-
ated airway inflammation is resistant to steroid treatment.43 Our
finding suggests that neutrophil-predominant airway inflammation
in asthmatic patients could also represent responses to bacterial
infection and not solely reflect steroidal effects. Although we
did not identify specific taxa associated with sputum neutrophil
values, this is not entirely surprising for in this cohort, sputum
neutrophil percentages were not found to be concordant with other
measures of airway inflammation.44
In summary, results of this study suggest the airway micro-
biome might be highly pertinent to non–type 2 pathways in
patients with severe asthma and influence manifestations of
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884 HUANG ET ALparticular disease features. Further dissection of the micro-
biome’s role in asthma-related immune responses will require
additional study of asthmatic patients with varying disease
severities and phenotypes and consideration of other microbiota
(eg, fungi). Our findings also suggest future mechanism-oriented
investigations of specific microbial targets. Future investigations
involving larger cohorts of patients with well-characterized
asthma will likely be necessary to dissect the complex relation-
ships between the airway microbiome and distinct asthma
phenotypes.
We thank Ali Faruqi for his guidance in the PICRUSt analyses.
Clinical implications: In patients with severe asthma, specific
airway bacterial microbiota are associated with clinical and in-
flammatory features, including obesity and asthma control, but
not markers of eosinophilic or type 2–related airway
inflammation.
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